QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.104.008086v1 67/5/1772    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zukunft, J. Articles by Zanger, U. M. Search for Related Content PubMed PubMed Citation Articles by Zukunft, J. Articles by Zanger, U. M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB 6-METHYLURACIL

ORIGINAL ARTICLE

A Natural CYP2B6 TATA Box Polymorphism (–82T C) Leading to Enhanced Transcription and Relocation of the Transcriptional Start Site

Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany (J.Z., T.R., K.K., M.S., M.E., U.M.Z.); EPIDAUROS Biotechnology AG, Bernried, Germany (T.L.); Department of Toxicology, Institute of Pharmacology and Toxicology, University of Goettingen, Goettingen, Germany (K.I.H.-E.); and Department of Surgery, Charité, Campus Virchow-Clinic, Humboldt University, Berlin, Germany (A.K.N.)

Abstract

We investigated the impact of promoter polymorphisms on transcription of the human CYP2B6 gene. In total, 98 DNA samples from white persons from a previously characterized liver bank were sequenced throughout 2.3 kilobases of upstream sequence and haplotype structures were determined using additional coding sequence information. HepG2 cells and primary rat and human hepatocytes were transfected with luciferase reporter gene constructs driven by 2033 base pairs (bp) of the most frequent promoter variants. The novel haplotype *22 (–1848C A, –801G T, –750T C, and –82T C) showed 3- to 9-fold enhanced transcriptional activity in all transfected cells. Constructs containing single mutations surprisingly revealed –82T C, predicted to disrupt a putative TATA box, to be alone responsible for this effect. In silico analysis and electrophoretic mobility shift assay demonstrated conversion of the putative TATA box into a functional CCAAT/enhancer-binding protein binding site. Analysis of transcriptional start sites showed the mutant promoter to be transcribed from a start site located approximately 30 bp downstream of the wild-type start site, consistent with the use of a noncanonical TATA box at –55 bp. Median CYP2B6 mRNA expression and bupropion hydroxylase activity as a selective marker of CYP2B6 catalytic activity were approximately 2-fold higher in livers genotyped –82TC as in those genotyped –82TT (20.4 versus 9.8 arbitrary units, p = 0.007, and 201.8 versus 106.7 pmol/mg/min, p = 0.042, respectively). This promoter polymorphism thus contributes to CYP2B6 functional variability and represents a novel mechanism by which mutations can enhance transcription. Furthermore, a detailed interspecies comparison of CYP2B promoters and transcriptional start sites provided novel insights into evolutionary relationships.

Received for publication October 11, 2004.

Accepted for publication February 18, 2005.

Address correspondence to: Dr. Ulrich M. Zanger, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstr. 112, 70376 Stuttgart, Germany. E-mail: uli.zanger{at}ikp-stuttgart.de

This article has been cited by other articles:

				J. Davaalkham, T. Hayashida, K. Tsuchiya, H. Gatanaga, D. Nyamkhuu, and S. Oka Allele and Genotype Frequencies of Cytochrome P450 2B6 Gene in a Mongolian Population Drug Metab. Dispos., October 1, 2009; 37(10): 1991 - 1993. [Abstract] [Full Text] [PDF]

				J. A. Williams, T. Andersson, T. B. Andersson, R. Blanchard, M. O. Behm, N. Cohen, T. Edeki, M. Franc, K. M. Hillgren, K. J. Johnson, et al. PhRMA White Paper on ADME Pharmacogenomics J. Clin. Pharmacol., July 1, 2008; 48(7): 849 - 889. [Abstract] [Full Text] [PDF]

				M. Pascual, M. J. Gomez-Lechon, J. V. Castell, and R. Jover ATF5 Is a Highly Abundant Liver-Enriched Transcription Factor that Cooperates with Constitutive Androstane Receptor in the Transactivation of CYP2B6: Implications in Hepatic Stress Responses Drug Metab. Dispos., June 1, 2008; 36(6): 1063 - 1072. [Abstract] [Full Text] [PDF]

				M. H. Hofmann, J. K. Blievernicht, K. Klein, T. Saussele, E. Schaeffeler, M. Schwab, and U. M. Zanger Aberrant Splicing Caused by Single Nucleotide Polymorphism c.516G>T [Q172H], a Marker of CYP2B6*6, Is Responsible for Decreased Expression and Activity of CYP2B6 in Liver J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 284 - 292. [Abstract] [Full Text] [PDF]

				J. K. Blievernicht, E. Schaeffeler, K. Klein, M. Eichelbaum, M. Schwab, and U. M. Zanger MALDI-TOF Mass Spectrometry for Multiplex Genotyping of CYP2B6 Single-Nucleotide Polymorphisms Clin. Chem., January 1, 2007; 53(1): 24 - 33. [Abstract] [Full Text] [PDF]

				M. Shebley, M. I. Jushchyshyn, and P. F. Hollenberg SELECTIVE PATHWAYS FOR THE METABOLISM OF PHENCYCLIDINE BY CYTOCHROME P450 2B ENZYMES: IDENTIFICATION OF ELECTROPHILIC METABOLITES, GLUTATHIONE, AND N-ACETYL CYSTEINE ADDUCTS Drug Metab. Dispos., March 1, 2006; 34(3): 375 - 383. [Abstract] [Full Text] [PDF]